Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1530324rdf:typepubmed:Citationlld:pubmed
pubmed-article:1530324lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:1530324lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1530324lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:1530324lifeskim:mentionsumls-concept:C0007120lld:lifeskim
pubmed-article:1530324lifeskim:mentionsumls-concept:C1522720lld:lifeskim
pubmed-article:1530324lifeskim:mentionsumls-concept:C0205282lld:lifeskim
pubmed-article:1530324lifeskim:mentionsumls-concept:C0887889lld:lifeskim
pubmed-article:1530324lifeskim:mentionsumls-concept:C0004599lld:lifeskim
pubmed-article:1530324lifeskim:mentionsumls-concept:C0684262lld:lifeskim
pubmed-article:1530324pubmed:issue10 Suppllld:pubmed
pubmed-article:1530324pubmed:dateCreated1992-10-20lld:pubmed
pubmed-article:1530324pubmed:abstractTextWe used fibrin clot (FC) as a carrier of anticancer drug (AD) to provide a novel therapy for patients with serious malignant pleural effusion. After evacuating the pleural fluid, we enhanced an "FC-AD" formation in the pleural cavity of the patient to prevent this kind of effusion from reaccumulating. In an attempt to enhance FC-AD formation, we used two different procedures; either, fibrinogen/AD/G.T.XIII (procedure I) or fibrin glue/AD (procedure II). G.T.XIII is our newly devised compound drug, composed of biodegradable gelatin (G), thrombin (T) and a blood coagulation factor XIII (XIII). This therapy was termed "Bio-Adhesio-Chemo (BAC) therapy." We conducted BAC therapy 52 times on 44 patients using procedure I and 4 times on 4 patients using procedure II. Complete remission of the effusion was obtained, overall, in 83%, partial remission in 17%, and no non-effective case. The improvement of PS of the patients treated was 73%. Nineteen patients could be discharged with this therapy. Toxic effects with BAC therapy were within Grade 2 in all cases. We could favorably enhance FC-AD formation, in every case, by both procedure I and II. BAC therapy is very promising as a novel cancer chemopleurodesis for patients with malignant pleural effusion.lld:pubmed
pubmed-article:1530324pubmed:languagejpnlld:pubmed
pubmed-article:1530324pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1530324pubmed:citationSubsetIMlld:pubmed
pubmed-article:1530324pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1530324pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1530324pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1530324pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1530324pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1530324pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1530324pubmed:statusMEDLINElld:pubmed
pubmed-article:1530324pubmed:monthAuglld:pubmed
pubmed-article:1530324pubmed:issn0385-0684lld:pubmed
pubmed-article:1530324pubmed:authorpubmed-author:KidoTTlld:pubmed
pubmed-article:1530324pubmed:authorpubmed-author:KawaharaTTlld:pubmed
pubmed-article:1530324pubmed:authorpubmed-author:SugitachiAAlld:pubmed
pubmed-article:1530324pubmed:authorpubmed-author:ShindohTTlld:pubmed
pubmed-article:1530324pubmed:issnTypePrintlld:pubmed
pubmed-article:1530324pubmed:volume19lld:pubmed
pubmed-article:1530324pubmed:ownerNLMlld:pubmed
pubmed-article:1530324pubmed:authorsCompleteYlld:pubmed
pubmed-article:1530324pubmed:pagination1640-3lld:pubmed
pubmed-article:1530324pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1530324pubmed:meshHeadingpubmed-meshheading:1530324-...lld:pubmed
pubmed-article:1530324pubmed:meshHeadingpubmed-meshheading:1530324-...lld:pubmed
pubmed-article:1530324pubmed:meshHeadingpubmed-meshheading:1530324-...lld:pubmed
pubmed-article:1530324pubmed:meshHeadingpubmed-meshheading:1530324-...lld:pubmed
pubmed-article:1530324pubmed:meshHeadingpubmed-meshheading:1530324-...lld:pubmed
pubmed-article:1530324pubmed:meshHeadingpubmed-meshheading:1530324-...lld:pubmed
pubmed-article:1530324pubmed:meshHeadingpubmed-meshheading:1530324-...lld:pubmed
pubmed-article:1530324pubmed:meshHeadingpubmed-meshheading:1530324-...lld:pubmed
pubmed-article:1530324pubmed:meshHeadingpubmed-meshheading:1530324-...lld:pubmed
pubmed-article:1530324pubmed:meshHeadingpubmed-meshheading:1530324-...lld:pubmed
pubmed-article:1530324pubmed:meshHeadingpubmed-meshheading:1530324-...lld:pubmed
pubmed-article:1530324pubmed:meshHeadingpubmed-meshheading:1530324-...lld:pubmed
pubmed-article:1530324pubmed:year1992lld:pubmed
pubmed-article:1530324pubmed:articleTitle[Locoregional therapy in patients with malignant pleural effusion--two different types of "BAC therapy"].lld:pubmed
pubmed-article:1530324pubmed:affiliationDept. of Surgery, Osaka National Hospital.lld:pubmed
pubmed-article:1530324pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1530324pubmed:publicationTypeEnglish Abstractlld:pubmed